Ocugen Reports Director/Officer Changes and Compensation
Ticker: OCGN · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, officer-appointment
TL;DR
Ocugen's 8-K shows board and exec shakeups, plus new pay deals.
AI Summary
Ocugen, Inc. filed an 8-K on December 18, 2025, reporting events as of December 12, 2025. The filing indicates changes related to the departure of directors or certain officers, the election of directors, and the appointment of certain officers, as well as compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive appointments can signal shifts in company strategy or leadership, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if numerous or unexpected, can indicate internal instability or strategic pivots that carry inherent risks.
Key Numbers
- 123610 — Accession Number (Unique identifier for the filing)
- 20251218 — Filing Date (Date the report was submitted to the SEC)
- 20251212 — Report Date (Date of the earliest event reported)
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- Malvern, Pennsylvania (location) — Principal Executive Offices
FAQ
What specific changes were made regarding directors or officers?
The filing indicates the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
Are there any new compensatory arrangements for officers mentioned?
Yes, the filing covers compensatory arrangements of certain officers.
When was this 8-K report filed with the SEC?
The report was filed on December 18, 2025.
What is the principal executive office address for Ocugen, Inc.?
The principal executive offices are located at 11 Great Valley Parkway, Malvern, Pennsylvania 19355.
What is the Commission File Number for Ocugen, Inc.?
The Commission File Number is 001-36751.
Filing Stats: 664 words · 3 min read · ~2 pages · Grade level 14 · Accepted 2025-12-18 17:17:28
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm2533891d1_8k.htm (8-K) — 24KB
- 0001104659-25-122610.txt ( ) — 184KB
- ocgn-20251212.xsd (EX-101.SCH) — 3KB
- ocgn-20251212_lab.xml (EX-101.LAB) — 33KB
- ocgn-20251212_pre.xml (EX-101.PRE) — 22KB
- tm2533891d1_8k_htm.xml (XML) — 3KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In the fourth quarter of 2025, the Compensation Committee (the " Compensation Committee ") of the Board of Directors (the " Board ") of Ocugen, Inc. (the " Company ") conducted a review, with its compensation consultant, of total equity ownership of the Company's Chief Executive Officer, Dr. Shankar Musunuri, as compared to founder chief executive officers in the Company's peer group. On December 12, 2025, upon recommendation of the Compensation Committee, the Board approved an additional award of 9,369,604 Performance Restricted Stock Units (the " PSUs ") to Dr. Musunuri, in addition to Dr. Musunuri's regular annual equity award, to be granted on January 2, 2026. The PSUs are subject to a three year performance period ending December 31, 2028 (the " Performance Period ") and will vest upon the Compensation Committee's determination of the Company's achievement of certain performance milestones as follows: (i) two-thirds of the PSUs will vest upon certain regulatory milestones and (ii) one-third of the PSUs will vest upon the achievement of a stock performance related milestone, in each case during the Performance Period. The performance milestones may be achieved (and the PSUs earned) at any time during the Performance Period, and the PSUs will vest and be settled in shares of the Company's Common Stock at such time as the Compensation Committee certifies that an applicable performance milestone has been achieved, subject to Dr. Musunuri's continued service with the Company through the applicable achievement date. Any PSUs for which a performance milestone has not been achieved by the end of the Performance Period will be cancelled and forfeited. Upon any termination of service, any portion of the PSUs that is unvested and unearned as of the termination date will be forfeited. SIGNATURE Pursuant to the